TEM1657 possesses very favorable features at pre-clinical stage,
making it a very promising therapeutic solution for psoriasis patients.

Very strong and rapid ability to alleviate psoriasis symptoms

Good safety profile

Stable at room temperature

Temisis uses a phenotypic cell-based assay to screen extensive libraries of compounds to identify first-in-class small molecules with high potential. This screening assay along with lead optimization allowed to discover TEM1657 and TEM1648.

Clinical trials are to start in 2023

  • TEM1648 is another asset in development to treat psoriasis.
  • TEM1657‘s future indications are atopic dermatitis, and Crohn’s disease.